Market Scope – 

The preimplantation genetic testing market size is expected to expand by USD 0.65 billion in 2032, with a CAGR of around 10.2% over the forecast period 2023-2032.

The Preimplantation Genetic Testing (PGT) market is witnessing notable growth as a pivotal component of assisted reproductive technology. This market offers insights into the genetic health of embryos before implantation, aiding in the selection of embryos free from genetic disorders. The increasing prevalence of genetic conditions, coupled with advancements in genomic technologies, fuels market expansion. PGT serves as a valuable tool for couples undergoing in vitro fertilization, enhancing the chances of a healthy pregnancy. Rising awareness, coupled with a growing global demand for fertility treatments, propels the Preimplantation Genetic Testing Market into a promising trajectory, addressing crucial aspects of reproductive health.

The preimplantation genetic testing market offers advanced diagnostic tools for assessing genetic abnormalities in embryos before implantation during in vitro fertilization (IVF). With preimplantation genetic diagnosis (PGD), couples can screen embryos for various genetic disorders, enhancing the success rates of IVF and reducing the risk of inherited diseases. This market's growth is driven by rising infertility rates and advancements in genetic testing technologies.

Market Segmentation – 

The global market for preimplantation genetic testing is systematically divided based on procedure, type, application, technology, product and service, end user, and region. In terms of procedure, it encompasses preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS). The PGD segment, facilitating the identification of over a hundred genetic conditions, is expected to dominate the market due to heightened awareness and increasing reliance on genetic defect-free pregnancies. 

The PGS segment is also poised for substantial growth in promoting healthy pregnancies. The embryo testing type is anticipated to exhibit favorable growth, especially in addressing the rising threat of chromosomal abnormalities. Regarding product and service, the reagents and consumables segment is expected to lead, driven by the escalating use of reagents in female infertility diagnostics. 

The technology segments, including next-generation sequencing and comparative genomic hybridization, are likely to command significant market shares due to reduced costs and enhanced mosaicism detection capabilities. The end-user landscape encompasses maternity centers, fertility clinics, hospitals, diagnostic labs, and research laboratories & academic institutes. Geographically, the market spans the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

Regional Analysis

The March of Dimes, a US voluntary health group, reported that 7.9 million children, constituting 6% of total births globally, are born with serious birth defects of genetic or partially genetic origin. This awareness stems from a study of 193 countries, highlighting the increasing prevalence of genetic defects and the growing global awareness of preimplantation genetic testing.

The US Department of Health & Human Services noted the commonality of infertility, affecting approximately 12 to 13 out of 100 couples in the US. With 6.1 million women aged 15 to 44 facing challenges in getting or staying pregnant, the demand for IVF procedures is expected to rise, driving the market.

In Europe, the escalating maternal age contributes to childbirth complications and an increased risk of chromosomal abnormalities, fostering a higher adoption of preimplantation genetic testing for ensuring healthy gene expression in newborns.

The Asia-Pacific Preimplantation Genetic Testing market outlook experiences significant growth, influenced by the active participation of market players.

Contrarily, the Middle East and Africa hold the smallest share in the global market, primarily due to low economic development, particularly in the African region

Key Players - 

Leading participants in the global preimplantation genetic testing market include Natera, Inc., CooperSurgical, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., IGENOMIX, Reprogenetics, LLC, Genea Limited, PerkinElmer, Inc., Genesis Genetics Ltd., Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., Bioarrayn Genetics, Laboratory Corporation of America Holdings, California Pacific Medical Center, and Reproductive Health Science Ltd. 

These key players contribute significantly to the advancements and growth of the preimplantation genetic testing market, offering innovative solutions and driving progress in the field of assisted reproductive technology.

For more information visit at MarketResearchFuture